Drug maker Dendreon seeking a buyer: report
(Reuters) - Drug maker Dendreon Corp is looking for a suitor after sales for its lead product, prostate cancer drug Provenge, were weaker than expected, according to a Bloomberg report.
The Seattle-based company is working with JPMorgan Chase & Co to help it find a buyer, Bloomberg said, citing people familiar with the matter.
Dendreon's troubles began in 2011 after the company withdrew its sales forecast for the drug. Questions have also emerged about the veracity of the clinical trials that led to Provenge's approval.
The company had said over the years that physician uncertainty about reimbursement and the need for added manufacturing capacity have contributed to slow sales for the drug.
Since Provenge's 2010 approval, easier-to-use and more effective prostate cancer treatments have also entered the market.
Revered by millions as a beacon of hope against oppression and as an archetype of reconciliation, Nelson Mandela leaves behind a grieving nation. Video
NEW YORK - U.S. stock index futures extended gains in volatile trading Friday after data showed employers hired more workers than expected in November and the jobless rate fell to a five-year low, which could fan speculation the Federal Reserve could soon start reducing its bond purchases program. | Video
SAN FRANCISCO - At Pinterest, the online bulletin board service that is valued near $3.8 billion, some 70 percent of the users are female. But the company's board of directors is 100 percent male.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.